You are here: Industry Insights > registration

News List

API Registration Process in Pakistan Saher Haider
April 07, 2025
APIs are the biologically active components in pharmaceutical drugs responsible for producing the intended therapeutic effects.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China PharmaSources
March 20, 2025
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
Japanese Pharmaceutical Market & Registration Strategies- Part 2 Deepak Hegde
November 12, 2024
The second article in the series focuses on strategies for success in registering products on the Japanese market.
Japanese Pharmaceutical Market & Registration Strategies – Part 1 Deepak Hegde
November 12, 2024
The article provides an outline of characteristics、Regulatory bodies、 Pricing、Reimbursement、the process of registering an innovative drug and generic drugs in Japan.
South Africa Ups Registration of New Pharmaceutical Products SHEM OIRERE
March 13, 2023
SAHPRA has recently announced completion of a review of 16,000 applications for new products and variations nearly four years after it took over from the former regulator, the Medicines Control Council.
Electronic Drug Registration and Listing (eDRLS) Lin Zhang
December 02, 2021
Last month (October 13, 2021), the Food and Drug Administration (FDA) held a conference that is part of the CDER Small Business & Industry Assistance (SBIA) Regulatory Education for Industry (REdI) series.
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin") PRNewswire
March 04, 2025
Raziel Therapeutics initiates phase 3 study in China for RZL-012 to reduce submental fat, partnering with JuveStar, product expected in 2027.
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China PharmaSources
November 15, 2024
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China